文献速递临床试验与 GCP基础与转化研究

依库珠单抗减轻动脉瘤性蛛网膜下腔出血后脑损伤的II期试验方案

CompLement C5 Antibodies for decreasing brain injury after aneurysmal Subarachnoid Haemorrhage (CLASH): study protocol for a randomised controlled phase II clinical trial.
PubMed 文献 · Trials · 2020-11-25

CLASH是一项随机、对照、开放标签、结局评估盲法的II期临床试验,旨在评估依库珠单抗(补体C5抗体)在动脉瘤性蛛网膜下腔出血后早期降低脑损伤的药效与安全性。主要结局为发病后第3天脑脊液C5a浓度,计划每组纳入20例患者。

要点

  • 依库珠单抗在aSAH后12小时内及第3、7天静脉给药1200mg。
  • 主要结局为第3天脑脊液C5a浓度,需26例完成脑脊液评估。
  • 干预组接受4周预防性抗生素,特定真菌培养阳性者加用抗真菌药。

核心结论

  • CLASH是首个探讨依库珠单抗在aSAH早期药效与安全性的试验。

研究设计与样本

  • 随机、对照、开放标签、结局评估盲法的II期临床试验。
  • 计划每组纳入20例患者,其中每组13例完成脑脊液评估。

关键数值与推荐

  • 依库珠单抗1200mg静脉给药,于发病后<12小时、第3天和第7天各一次。
  • 主要结局为发病后第3天脑脊液C5a浓度。
  • 次要结局包括不良事件、血液和脑脊液炎症参数、MRI脑梗死及临床和认知结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The inflammatory response after aneurysmal subarachnoid haemorrhage (aSAH) has been associated with early brain injury, delayed cerebral ischaemia, poor functional outcome, and case fatality. In experimental SAH studies, complement C5 antibodies administered shortly after SAH reduced brain injury with approximately 40%. Complement component C5 may be a new therapeutic target to reduce brain injury and hereby improve the outcome after aSAH. We aim to investigate the pharmacodynamic efficacy and safety of eculizumab (complement C5 antibody) in patients with aSAH. METHODS: A randomised, controlled, open-label, phase II clinical trial with blinded outcome assessment. Eculizumab (1200 mg) is administered intravenously < 12 h, on day 3 and on day 7 after ictus. Patients in the intervention group receive prophylactic antibiotics for 4 weeks, and those with a central line or an external ventricular shunt and a positive fungal or yeast culture also receive prophylactic antifungal therapy for 4 weeks. The primary outcome is C5a concentration in the cerebrospinal fluid (CSF) on day 3 after ictus. Secondary outcomes include the occurrence of adverse events, inflammatory parameters in the blood and CSF, cerebral infarction on magnetic resonance imaging, and clinical and cognitive outcomes. We aim to evaluate 26 patients with CSF assessments, 13 in the intervention group and 13 in the comparator group. To compensate for early case fatality and inability to obtain CSF, we will include 20 patients per group. DISCUSSION: The CLASH trial is the first trial to investigate the pharmacodynamic efficacy and safety of eculizumab in the early phase after aSAH. TRIAL REGISTRATION: Netherlands Trial Register NTR6752 . Registered on 27 October 2017 European Clinical Trials Database (EudraCT) 2017-004307-51.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Koopman I, Rinkel GJE, Vergouwen MDI, et al. CompLement C5 Antibodies for decreasing brain injury after aneurysmal Subarachnoid Haemorrhage (CLASH): study protocol for a randomised controlled phase II clinical trial. Trials. 2020. PMID: 33239044. doi:10.1186/s13063-020-04838-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。